Koninklijke Philips N.V. - ADR

Q3 headline performance: strong orders, sales growth and margin expansion - Order intake: +8% YoY (and +4% YTD) driven by sustained demand and traction from new innovations. - Comparable sales: ~+3% in Q3 (YTD within the 3.5% full-year range), supported by Personal Health and Connected Care strength. - Diagnosis & Treatment (D&T): broadly flat in Q3 due to ultrasound shipment phasing and lower China sales (as flagged in Q2). - Profitability: Adjusted EBITA margin +70 bps to 13% in Q3 (ahead of expectations). Group margin expansion across segments; productivity + innovation offset inflation.

Cash flow, balance sheet and capital allocation (including buybacks) - Free cash flow (FCF): EUR 384m inflow in Q3 (vs EUR 172m in Q3 last year), mainly due to higher cash earnings and lower working capital outflows. - Balance sheet: EUR 2.8bn cash, net debt EUR 5.4bn, with net debt/adjusted EBITA down to 1.7x (vs 2.2x a year ago). - Capital allocation priorities: organic growth first, then dividend (scrip dividend), then selective M&A, with share buybacks evaluated periodically (not the top priority). - Green bond: issued EUR 650m EU Green Bond (2.7x oversubscribed).

Respironics legal/provision: major negative but also an important step - U.S. DOJ agreement in principle on Respironics-related recall consequences. - Philips recorded a provision of EUR 288m. - Management framed this as an important step toward resolution, while noting other proceedings remain (e.g., U.S. State Attorneys General investigation), which are excluded from the outlook assumptions.